Indications for Insulin Use in Type 2 Diabetes
Insulin should be initiated immediately in type 2 diabetes when HbA1c is ≥10% (≥86 mmol/mol) or blood glucose is ≥300 mg/dL (≥16.7 mmol/L), or when catabolic symptoms are present (unexpected weight loss, polyuria, polydipsia, ketosis, or hypertriglyceridemia), regardless of other glucose-lowering therapies being used 1, 2.
Primary Indications for Insulin Initiation
Immediate/Urgent Indications
Insulin is essential and should be started without delay in the following situations:
- Severe hyperglycemia: HbA1c >10% or blood glucose ≥300 mg/dL 1, 2
- Catabolic features present: Unexpected weight loss, ketosis, or hypertriglyceridemia 2
- Symptomatic hyperglycemia: Polyuria, polydipsia, or other hyperglycemic symptoms 1, 3
- Acute illness or surgery 3
- Pregnancy 3
These situations represent the "5S" framework: Severe hyperglycemia, Symptomatic diabetes, Sick diabetes (acute/chronic comorbidity), Special situations (pregnancy), and Secondary diabetes (pancreatic, drug-induced, endocrine disorders) 4.
Sequential Indications (After Oral Agent Failure)
When oral medications and lifestyle modifications have been optimally used:
- HbA1c ≥7.5% (≥58 mmol/mol): Consider insulin alone or in combination with oral agents 3
- HbA1c remains above individualized target: Despite optimized non-insulin therapy 5
- Basal insulin dose >0.5 U/kg/day with HbA1c still above target: Progress to combination injectable therapy 5
Clinical Context and Nuances
The 2017 ADA guidelines emphasize that diabetes is a progressive condition and many patients will eventually require and benefit from insulin therapy 5. Early patient education about expected disease progression is critical—avoid using insulin as a threat, as this makes the transition more difficult 5.
A key distinction: While traditional stepwise approaches add insulin late in the disease course, emerging evidence supports earlier insulin use in specific populations. Short-term intensive insulin therapy in newly diagnosed patients with HbA1c >9% can restore β-cell function, improve first-phase insulin secretion, and potentially induce drug-free remission in 42-66% of patients at various time points 6. This challenges the conventional "insulin as last resort" paradigm.
Special Populations Requiring Insulin
- Advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²): GLP-1 RA is preferred, but insulin may be necessary 1, 7
- Liver cirrhosis 7
- Post-transplant diabetes 7
- Contraindications to or failure of oral agents 3
Practical Initiation Approach
When starting insulin 5:
- Begin with basal insulin: 10 units or 0.1-0.2 units/kg/day
- Continue metformin and sometimes one additional non-insulin agent
- Titrate dose: Increase by 10-15% (or 2-4 units) once or twice weekly until fasting glucose targets are met
- Consider cost: NPH insulin is more affordable than newer analogues, though newer products cause less hypoglycemia 5
When to Intensify Beyond Basal Insulin
If HbA1c remains above target on optimally titrated basal insulin 5:
- Add rapid-acting insulin before the largest meal (4 units, 0.1 U/kg, or 10% of basal dose)
- Consider GLP-1 RA addition (associated with weight loss and less hypoglycemia) 5
- Switch to twice-daily premixed insulin 5
Common Pitfalls to Avoid
Do not delay insulin when clear indications exist—therapeutic inertia is a major barrier to optimal diabetes management 7, 8. The fear of hypoglycemia, injection stigma, and perceived treatment failure contribute to delays, but these concerns are often overestimated by both patients and providers 7.
Monitor for overbasalization: Signs include basal dose >0.5 units/kg/day, significant bedtime-to-morning glucose differential, hypoglycemia episodes, or high glycemic variability 1. When this occurs, promptly reevaluate and consider adding prandial insulin or switching regimens.
Reassess other glucose-lowering agents when starting insulin: Continue metformin for ongoing benefits, but reduce or discontinue sulfonylureas and meglitinides to minimize hypoglycemia risk 1.